SHIRE REPORTS POSITIVE RESULTS FROM MTS STUDY

Shire has announced that its investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in the symptoms of attention-deficit/hyperactivity disorder (ADHD) and was generally well tolerated in patients aged 6 to 12 in two clinical trials.

The MTS patch combines the active ingredient of methylphenidate with Noven's patented DOT Matrix transdermal technology. This transdermal delivery system was designed to provide continuous medication release throughout the day. The transdermal system releases medication that passes through the skin and directly into the bloodstream.

Data from Phase II and Phase III clinical trials demonstrated statistically significant improvements in the primary and secondary endpoints analyzed for children treated with MTS compared to children treated with placebo.

The Phase II analog classroom study included 79 children with ADHD. The patch was worn for nine hours, and efficacy was assessed throughout the day for twelve hours. MTS demonstrated statistically significant improvement over placebo on the measures tested.